Safety, Tolerability, and Preliminary Efficacy of NouvNeu001 for the Treatment of Advanced Parkinson’s Disease: A Multi-center, Open Label, Phase 1 Study
Objective: This Phase 1 study aims to evaluate the safety, tolerability, preliminary efficacy, and optimal dose of NouvNeu001 for treating mid to late-stage Parkinson’s disease…The Feedback Loop: Illness Perceptions and Motor Complications in Parkinson’s
Objective: To explore the relationship between motor complications, illness perceptions and cognitive beliefs about symptoms in people with Parkinson's disease (PwP). Background: Around 50% PwP…Antiparkinson Medication Reduces the Probability of the Multiple Step Saccade Pattern During a Memory-Guided Saccade Task
Objective: We wanted to determine how the multiple step saccade pattern responds to antiparkinson medication, as it has been proposed to use this pattern as…VQ-101, a CNS-Penetrant Small Molecule Allosteric Activator of Glucocerebrosidase (GCase), Demonstrates Favorable Tolerability and Sustained Activation of Lysosomal GCase in Individuals with Parkinson’s Disease
Objective: To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of VQ-101 in healthy volunteers (HVs), and individuals with Parkinson’s disease (PD) with and without GBA1…The Effect of Foslevodopa/Foscarbidopa Treatment on Nonmotor Symptom Burden in Advanced Parkinson’s Disease
Objective: To investigate the impact of foslevodopa/foscarbidopa (LDp/CDp) on nonmotor symptoms (NMS) in adults with advanced Parkinson’s disease (aPD). Background: LDp/CDp, a 24-hour per day…Inpatient Multimodal Intensive Care in Moderately Advanced Parkinson’s Disease: Role Of Medication Adjustment In Outcome Measures
Objective: In this study, we wish to determine whether medication changes play a major role in the improvements observed after in-patient multimodal intensive neurorehabilitation and…Opicapone improves end-of-dose neuropsychiatric fluctuations in patients with Parkinson’s disease
Objective: We aim to evaluate the efficacy of Opicapone (OPC) on end-of-dose neuropsychiatric fluctuations, the most frequent and severe non-motor fluctuations (NMF) in Parkinson’s disease (PD) patients [1].…Evaluation of the Pharmacodynamic Effects of BIIB122/DNL151 in Participants with LRRK2 mutation-driven Parkinson’s disease (BEACON Study)
Objective: To characterize the biomarker effects of BIIB122/DNL151 in participants with LRRK2 pathogenic mutations diagnosed with Parkinson’s disease (LRRK2-PD). Background: BIIB122/DNL151 is a CNS-penetrant small…Plasma Protein Profiles Reveal Distinct Molecular Signatures in Parkinson’s Disease and Multiple System Atrophy
Objective: We aimed to identify distinct plasma proteins in patients with Parkinson’s disease (PD) and multiple system atrophy (MSA) and evaluate their associations with disease…A Prospective, Observational Study to Identify Biomarkers in Parkinsonian Syndromes (proATYP).
Objective: This is a prospective observational study to identify biomarkers in parkinsonian syndromes. Background: Parkinson’s disease (PD) and atypical parkinsonian syndromes namely progressive supranuclear palsy…
- « Previous Page
- 1
- …
- 34
- 35
- 36
- 37
- 38
- …
- 436
- Next Page »